We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Whole-Blood Testing Diagnoses Acute Zika Virus Infections

By LabMedica International staff writers
Posted on 04 Jul 2019
Print article
Image: The RealStar Zika Virus reverse transcription polymerase chain reaction (RT-PCR) (Photo courtesy of Altona Diagnostics).
Image: The RealStar Zika Virus reverse transcription polymerase chain reaction (RT-PCR) (Photo courtesy of Altona Diagnostics).
Zika virus infections are linked to congenital malformations in neonates from mothers infected during pregnancy and to neurologic disorders in adults. Reverse transcription polymerase chain reaction (RT-PCR) is the most reliable method for confirming Zika virus infections.

The stakes for an accurate diagnosis are high when congenital Zika syndrome might be involved, such as in diagnosis in pregnant women and their partners, because Zika virus infections can be sexually transmitted. Diagnostics are based on Zika virus RNA detection, detection of Zika virus–specific antibodies, or both.

Scientists at the Erasmus Medical Center (Rotterdam, the Netherlands) compared Zika virus quantitative reverse transcription PCR (qRT-PCR) results for 249 EDTA–whole blood and EDTA–plasma pairs submitted for laboratory testing from 227 patients with suspected Zika virus infection during July 2016–May 2017.

For testing, they spiked the samples with an internal control and extracted total nucleic acids from a 500-μL sample in 100 μL of eluate using the MagNAPure 96 DNA and Viral NA large volume kit and Viral NA Universal LV 2.0 protocol. They confirmed all Zika virus RNA−positive samples using a commercial Zika virus qRT-PCR.

The team detected Zika virus RNA in 31 (12.4%) of 249 whole-blood samples and in 23 (74.2%) of the 31 corresponding plasma samples. The 31 positive whole-blood samples were collected from 31 individual patients. This comparison indicated that eight additional Zika virus–positive patients would have been identified if whole blood had been used routinely instead of plasma. This finding represented a 34% increase in confirmed cases of Zika virus infection.

The scientists tested urine and plasma by qRT-PCR and tested serum by ELISA for the presence of Zika virus–specific IgM and IgG. For three of the eight additional patients, Zika virus infection had already been confirmed on the basis of the presence of Zika virus RNA and IgM in an earlier plasma sample. For the remaining five patients, only a status of probable case was achieved without the whole blood testing.

The authors concluded that that individual patient care might benefit from whole-blood testing in a routine diagnostic laboratory setting, thereby possibly reducing the need for more specialized serology (i.e., comparative flavivirus neutralization tests) to confirm cases based on serology. Therefore, they have implemented whole blood RT-PCR testing for Zika virus diagnostic requests in our routine diagnostic setup. The study was published in the July 2019 issue if the journal Emerging Infectious Diseases.

Related Links:
Erasmus Medical Center

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.